Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01406938
First received: July 12, 2011
Last updated: January 5, 2015
Last verified: January 2015

July 12, 2011
January 5, 2015
August 2011
May 2013   (final data collection date for primary outcome measure)
  • For the fixed interval group, the percentage of Participants (who responded to treatment at week 12) maintaining a 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at week 52 [ Time Frame: Week 40 , week 52 ] [ Designated as safety issue: No ]
    PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)
  • For the start of relapse (SoR) group, % of Participants maintaining a 75% Improvement from baseline in Psoriasis Area and Severity Index (PASI) Score at week 52 and week 40 when treatment was restarted [ Time Frame: Week 40 , week 52 ] [ Designated as safety issue: No ]
    PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)
Proportion of subjects who maintain Psoriasis Area and Severity Index 75 (PASI 75) response relative to baseline after having achieved PASI 75 response after 12 weeks of treatment with secukinumab [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01406938 on ClinicalTrials.gov Archive Site
  • Percentage of Participants achieving a 50%, 75%, 90% or 100% Improvement from baseline in (PASI ) Score and an Investigator's Global Assessment modified 2011 (IGA) 2011 score of 0 or 1 at week 2, 4, 6, 8, 12,16, 20, 24,28,32,36,40,44,48,and Week 52 [ Time Frame: Baseline, week 2, , 4, 6, 8, 12 ,16,20,24,28,32,36,40,44,48,and Week 52 ] [ Designated as safety issue: No ]
    PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)
  • Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) score and IGA mod 2011 0 or 1 score over time at week 12 and 52 [ Time Frame: Baseline, week 2, 4, 6, 8, 12 ,16,20,24,28,32,36,40,44,48, and Week 52 ] [ Designated as safety issue: No ]
    The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe. The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe
  • Change from baseline in EQ-5D at each visit, up to week 52. [ Time Frame: Baseline to week 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52. ] [ Designated as safety issue: No ]
    ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example "confined to bed") A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)
  • Change from Baseline in Dermatology Life Quality Index (DLQI) score. up to week 52 [ Time Frame: Baseline to week 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52. ] [ Designated as safety issue: No ]
    The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions
  • % of participants achieving a DLQI score of 0 or 1 at each visit up to week 52. [ Time Frame: Baseline to week 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52 ] [ Designated as safety issue: No ]
    The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions
  • Median Time to relapse (weeks) from Week 12. [ Time Frame: Week 12 to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52. ] [ Designated as safety issue: No ]
    Median time to relapse (weeks) from week 12. Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline
  • Percent of Responders with PASI equal to or greater than 50, PASI 75, PASI 90, PASI 100 and Percent of responders with IGA score of 0 or 1 who failed to respond to a previous biologic psoriasis therapy [ Time Frame: Week 12, week 52 ] [ Designated as safety issue: No ]
    Response variables PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response by visit were tabulated versus previous psoriasis systemic therapy and response to previous biologic systemic therapy, by treatment group. (This is covered by subgroup analyses)
  • Number of visits with PASI 50, 75, 90, 100 score and IGA mod 2011 0 or 1 [ Time Frame: Week 16, 20, 24,28,32,36,40,44,48,and Week 52 ] [ Designated as safety issue: No ]
    Number of visits with participants achieving a PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response
  • Number of secukinumab injections needed to regain PASI 75 response from start of relapse after week 12 [ Time Frame: week 16, 20, 24,28,32,36,40,44,48,and Week 52 ] [ Designated as safety issue: No ]
    The number of secukinumab injections needed for participants to regain PASI 75 response from the start of relapse after week 12
  • Number of participants developing anti-secukinumab antibodies [ Time Frame: Baseline, weeks 12, 24, 52 and 60 ] [ Designated as safety issue: No ]
    The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment. The number of participants developing anti-secukinumab anti-bodies was measured from Baseline to week 12, 24, 52 and 8 weeks after treatment at week 60
Proportion of subjects who achieve PASI 50/75/90/100 response or Investigator's Global Assessment (IGA) 0 or 1 response relative to baseline after 12 weeks and after 52 weeks of treatment with secukinumab [ Time Frame: 12 and 52 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen

This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Moderate to Severe Plaque-type Psoriasis
  • Drug: AIN457 150mg
    (1 injection per dose) and placebo to secukinumab 150 mg
    Other Name: secukinumab 150 mg
  • Drug: AIN457 300mg
    secukinumab 150 mg (2 injections per dose)
    Other Name: secukinumab
  • Experimental: AIN457150 mg- Induction period Only(IPO)
    secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
    Intervention: Drug: AIN457 150mg
  • Experimental: AIN457 300 mg - IPO
    secukinumab- 2 x 150mg injections per dose
    Intervention: Drug: AIN457 300mg
  • Experimental: AIN457 150 mg - Fixed Interval (FI)
    1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
    Intervention: Drug: AIN457 150mg
  • Experimental: AIN457 300 mg FI
    2 s.c. secukinumab 150 mg injections
    Intervention: Drug: AIN457 300mg
  • Experimental: AIN457 150 mg- Start of relapse (SoR)
    1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
    Intervention: Drug: AIN457 150mg
  • Experimental: AIN457 300 mg- SoR
    2 s.c. secukinumab 150 mg injections
    Intervention: Drug: AIN457 300mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
967
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.

Severity of disease meeting all of the following three criteria:

  • PASI score of 12 or greater,
  • Investigator's Global Assessment (IGA) score of 3 or greater
  • Total body surface area (BSA) affected of 10% or greater.
  • Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.

Exclusion criteria:

  • Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).
  • Current drug-induced psoriasis.
  • Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.
  • Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.
  • Hematological abnormalities.
  • History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.
  • History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.
  • Pregnant or nursing (lactating) women.
  • Other protocol-defined inclusion/exclusion criteria may apply.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Austria,   Bulgaria,   Canada,   Czech Republic,   France,   Germany,   India,   Italy,   Japan,   Poland,   Singapore,   Slovakia,   Switzerland,   United Kingdom,   Vietnam
 
NCT01406938
CAIN457A2304, 2011-000767-27
Yes
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP